Depatuxizumab mafodotin
Depatuxizumab mafodotin (pronunciation: deh-pah-tux-ih-zoo-mab maf-oh-doh-tin) is a monoclonal antibody-drug conjugate designed for the treatment of glioblastoma, a type of brain tumor.
Etymology
The name "Depatuxizumab mafodotin" is derived from the components of the drug. "Depatuxizumab" refers to the monoclonal antibody that targets the epidermal growth factor receptor (EGFR), and "mafodotin" refers to the cytotoxic drug that is attached to the antibody.
Mechanism of Action
Depatuxizumab mafodotin works by binding to the EGFR on the surface of cancer cells. Once bound, the drug is internalized by the cell, where the cytotoxic drug mafodotin is released. This drug then interferes with the cell's ability to divide and grow, leading to cell death.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Epidermal growth factor receptor (EGFR): A protein found on the surface of some cells to which epidermal growth factor binds, causing the cells to divide.
- Glioblastoma: A fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord.
- Cytotoxic drug: A medication that kills cells, especially cancer cells.
See Also
External links
- Medical encyclopedia article on Depatuxizumab mafodotin
- Wikipedia's article - Depatuxizumab mafodotin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski